Free Trial

Radiopharm Theranostics (RADX) FDA Approvals

Radiopharm Theranostics logo
$6.20 +0.14 (+2.31%)
As of 10/3/2025 03:55 PM Eastern

Radiopharm Theranostics' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Radiopharm Theranostics (RADX). Over the past two years, Radiopharm Theranostics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as RAD202, RV-01, RAD, 177Lu-RAD20, and 18F-RAD101. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

RAD202 FDA Regulatory Events

RAD202 is a drug developed by Radiopharm Theranostics for the following indication: to treat HER2-positive advanced and metastatic cancers. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

RV-01 FDA Regulatory Events

RV-01 is a drug developed by Radiopharm Theranostics for the following indication: For the 4Ig isoform. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

RAD 101 FDA Regulatory Events

RAD 101 is a drug developed by Radiopharm Theranostics for the following indication: For for successful detection of brain metastases. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

177Lu-RAD20 FDA Regulatory Events

177Lu-RAD20 is a drug developed by Radiopharm Theranostics for the following indication: In patients with PD-L1 positive advanced cancers. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

18F-RAD101 FDA Regulatory Events

18F-RAD101 is a drug developed by Radiopharm Theranostics for the following indication: in suspected recurrent brain metastasis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Radiopharm Theranostics FDA Events - Frequently Asked Questions

In the past two years, Radiopharm Theranostics (RADX) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Radiopharm Theranostics (RADX) has reported FDA regulatory activity for the following drugs: RAD 101, 177Lu-RAD20, RAD202, RV-01 and 18F-RAD101.

The most recent FDA-related event for Radiopharm Theranostics occurred on October 1, 2025, involving RAD202. The update was categorized as "Recommendation," with the company reporting: "Radiopharm Theranostics announced that it has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 75mCi in the Phase 1 ‘HEAT' clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. T"

Current therapies from Radiopharm Theranostics in review with the FDA target conditions such as:

  • For for successful detection of brain metastases - RAD 101
  • In patients with PD-L1 positive advanced cancers - 177Lu-RAD20
  • to treat HER2-positive advanced and metastatic cancers - RAD202
  • For the 4Ig isoform - RV-01
  • in suspected recurrent brain metastasis. - 18F-RAD101

More FDA Event Resources from MarketBeat

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

This page (NASDAQ:RADX) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners